Abstract-Quantification of uncertainties in doses from intakes of radionuclides is important in risk assessments and epidemiologic studies of individuals exposed to radiation. In this study, the uncertainties in the doses per unit intake (i.e., dose coefficients) for ingestion of 131 Sr, the dose coefficients represent exposure in adulthood and they were determined for all organs of radiological importance. The uncertainty in the estimated dose coefficients represent state of knowledge estimates for a reference individual, and they are described by lognormal distributions with a specified geometric mean (GM) and geometric standard deviation (GSD). The estimated geometric means vary only slightly from the dose coefficients reported by ICRP publications. The largest uncertainty is observed in the dose coefficients for bone surface (GSD ‫؍‬ 2.6), and red bone marrow (GSD ‫؍‬ 2.4) in the case of ingestion of 90 Sr. For most other organs, the uncertainty in the 90 Sr dose coefficients is characterized by a GSD of 1.8 (or less for some organs). For 131 I, the uncertainty in the thyroid dose coefficients is well represented by a GSD of 1.7 for both sexes and all ages other than infants for whom a GSD of 1.8 is more appropriate. The lowest uncertainties are obtained for the dose coefficients from ingestion of 137 Cs (GSD ‫؍‬ 1.24 for males; 1.4 for females). A dominant source of uncertainty in the ingestion dose coefficients is the variation of the biokinetic parameters. 
INTRODUCTION

Background
Ingestion of radioactive material is a major contributor to the doses to members of the public exposed to accidental or routine releases of radioactivity and a potential exposure pathway for workers in the nuclear industry. Radiation doses expressed per unit intake (Gy Bq Ϫ1 or Sv Bq Ϫ1 ) are usually referred to as "dose coefficients," "dose factors," or "dose conversion factors." Dose coefficients published to date are regarded as central estimates for large populations. Within any given human population, people differ substantially from each other, and there are differences among human populations as well. Many physical and physiological parameters influencing absorption and movement of a radioactive substance in the human body vary from one individual to another, introducing uncertainties due to inter-individual variability. In addition, some parameters are not well known, and one must therefore deal with uncertainty due to lack of knowledge about the true means and variances of these parameters. The two types of uncertainty can be combined if the assessment end point is the lack of knowledge in the dose to a reference individual, but they must be separated if the assessment end point is a variability of doses in a population (e.g., a cohort used for epidemiological studies ; IAEA 1989; NCRP 1996) .
In many exposure assessment studies, doses are estimated for a hypothetical individual, often referred to as a "target" or "reference" individual, who is assumed to be representative of members of a given population. By accepting the existence of uncertainty, one accepts the possibility that the dose to a real individual could be greater or less than the dose to the "reference" individual obtained using standard dose coefficients.
Uncertainties in dosimetry can affect the outcome of an epidemiological study. Such an effect was shown for the Japanese Survivors of the atomic bombings of Hiroshima and Nagasaki (Pierce et al. 1990 ). The random errors associated with an individual survivor dose were on the order of 30 -40% and produced an increase in the estimated excess relative risk per unit dose (ERR 1Sv ), as compared to the ERR 1Sv obtained by ignoring the random errors, of 4.3-7.2% for leukemia and of 6.8 -11.4% for all other cancers combined.
The importance of uncertainty in dosimetry has long been recognized, but only recently have there been attempts to quantify it. In the early 1980's, the analysis of uncertainty in internal dosimetry was called "imprecision analysis." Uncertainties in the doses to the thyroid from ingestion of 131 I were estimated by Dunning and Schwartz (1981) and later by Killough and Eckerman (1986) . Schwartz and Dunning (1982) analyzed the imprecision induced by the variability of the biological characteristics in estimating the effective dose from ingestion of 137 Cs. As part of the effort to reconstruct doses to off-site individuals exposed to fallout from nuclear weapons tests at the Nevada Test Site, an analysis of the uncertainties in dose factors for 89/90 Sr, 136/137 Cs, and 131 I was performed by Ng et al. (1990) and for 131 I by the NCI (1997) . The uncertainties in the thyroid dose factors from ingestion of 131 I by adults were re-estimated by Hamby and Benke (1999) and Harvey et al. (2003) using a more complex biokinetic model. The reconstruction of doses from historical releases of radioactivity from the Oak Ridge Reservation prompted an evaluation of the uncertainties in the ingestion dose factors for 131 I, 137 Cs, 90 Sr, and, for the first time, for 60 Co and 106 Ru (Apostoaei et al. 1998 (Apostoaei et al. , 1999a (Apostoaei et al. , 1999b . The uncertainty in the dose coefficients for ingestion of 90 Sr by adults was further investigated by Apostoaei (2001) .
In a few cases, uncertainties in ingestion dose factors have been estimated by eliciting the opinion of dosimetry experts. By analyzing the available biokinetic data and their relevancy to the human population, the experts were asked to make subjective (or judgmental) statements about the uncertainty in the dose factors. Bouville et al. (1994) estimated the uncertainties in the effective ‡ dose coefficients for 23 radionuclides. The uncertainties were expressed as "a factor of n." The limits of a 90% confidence interval for each dose coefficient were obtained by dividing and multiplying, respectively, the ICRP recommended ingestion dose factor by n.
In 1998 the Nuclear Regulatory Commission (NRC) and the Commission of the European Community (CEC) published an expert elicitation report for uncertainties in internal dosimetry (Goossens et al. 1998 ). However, this report showed large discrepancies between both the central values and the magnitude of uncertainty in the dose factors produced by individual experts.
Recently, the U.S. Environmental Protection Agency (U.S. EPA) published Federal Guidance Report No. 13 (Eckerman et al. 1999) , which provides radionuclide-specific radiogenic cancer risk coefficients for the U.S. population based on age-dependent dosimetry and risk models. The risk coefficients for ingestion (risk Bq Ϫ1 ) are obtained by integrating the timedependent absorbed dose-rate to a given tissue multiplied by the cancer risk per unit absorbed dose. To analyze the uncertainties, the risk coefficients are grouped in a few broad categories. The risk coefficients for ingestion of 137 Cs, 90 Sr, and 131 I have been assigned to categories having uncertainty factors of 4, 5, and 7, respectively.
Currently, both the National Council on Radiation Protection and Measurements (NCRP) and the International Commission on Radiological Protection (ICRP) are investigating the reliability of ingestion dose coefficients. NCRP has already published a report (NCRP 1998) that addresses the problem of uncertainties in the internal dosimetry in a general manner, discussing the sources of uncertainty in the gastrointestinal tract model, the respiratory tract model, the biokinetic models and the dosimetric models.
The study focuses on "reference" individuals who are assumed to be in a good state of health. The results for adults are applicable to both members of the public and radiation workers. The magnitude of uncertainties in the dose coefficients from ingestion of 131 I, 137 Cs, and 90 Sr are expressed for each sex and for various ages at exposure. This paper brings a number of advancements in the area of uncertainty in internal dosimetry. The analysis for ingestion of 131 I makes use of the most recent thyroid mass measured by ultrasonography, a method that is less prone to errors than autopsy and that allows in-vivo examinations of large populations. The dose coefficients for 137 Cs are obtained using the relationship between the biological half-lives and the amount of potassium in the human body. For 90 Sr, the most recent ICRP biokinetic model was used to derive the uncertainties. Also, as opposed to previous studies that addressed the uncertainty in effective doses, this work focuses on doses to specific organs.
MATERIALS AND METHODS
The dose coefficients are derived using the ICRP methodology (ICRP 1979; Eckerman 1994) . The dose for a unit intake is given by the total energy deposited by radiation in the target organ divided by the mass of the organ. The total energy deposited is calculated as the number of nuclear transformations (nt) occurring in any source organ multiplied by the energy deposited in the target organ by each nuclear transformation. The number of nuclear transformations is given by the integrated activity in the source organ, which, in turn, is predicted by the biokinetic model. The dosimetric model gives the energy deposited per nuclear transformation.
To estimate uncertainties in the dose coefficients, available human metabolic data were collected and analyzed to derive the uncertainty in the parameters of the biokinetic model. Necessary correlations between the parameters were imposed when calculations were performed. Similarly, the available data on the masses of the target organs and on the fraction of energy deposited in the target organ were gathered, and uncertainties about these quantities were expressed.
Probability language was used to express the uncertainties. Probability distributions were defined for all biokinetic and dosimetric parameters, and the MonteCarlo method was used for propagation of uncertainties in the derivation of the dose coefficients. The calculated ingestion dose coefficients are obtained as probability distributions. The uncertainties around a geometric mean (GM) are presented as geometric standard deviations (GSD) and also as 95% confidence intervals of these distributions.
The most important contributors to the uncertainty in a given organ dose coefficient are determined using a method called "sensitivity analysis" (NCRP 1996) or "importance analysis" (Morgan and Henrion 1990) , based on the rank correlations between the calculated dose coefficient and each individual biokinetic and dosimetric parameter. The individual parameters contributing to the dose coefficients are then grouped into three categories for a clearer summarization and interpretation of the results: a) the biokinetic model, which accounts for the number of nuclear transformations in a given source organ as obtained by integrating the time-dependent activities predicted by the biokinetic model; b) the energy deposition, which accounts for the absorbed Buzulukov and Dobrynin 1993; Mokrov et al. 2000; UNSCEAR 2000; Hoffman et al. 2002; Bouville et al. 2002. b 1 PBq ϭ 10 15 Bq. c This denotes the activity released from worldwide nuclear weapons tests, available to be deposited onto the ground as fallout. It includes the contribution of the detonations at the Nevada Test Site. fraction (AF); and c) the mass, which accounts for the mass of the target organ and for the whole-body mass. Determination of the most important contributors to the uncertainty is a powerful method to identify directions for further research that can lead to increased accuracy and decreased uncertainty in dose estimation. The following sections present the details of the methods used for each individual radionuclide.
The dose coefficients are reported in units of "Sv Bq Ϫ1 ", where "Sv" represents the equivalent dose obtained using a radiation-weighting factor equal to 1.0, with no associated uncertainty. When estimating risk from exposure to radiation, the effectiveness of different types of radiation should be taken into account by using factors (Kocher et al. 2003) specially determined for the reference radiation of concern, and for which the uncertainties have been quantified. It is expected that such radiation effectiveness factors are still unity for ingestion of 137 Cs and 90 Sr, but they may be larger than 1.0 for ingestion of 131 I.
I
After contaminated food is ingested, 131 I is rapidly and almost completely absorbed into the bloodstream (ICRP 1989) , from where it is metabolized in the same manner as stable iodine. Iodine is used by the thyroid gland in production of two significant thyroid hormones, thyroxine (T4) and triiodothyronine (T3). After formation, the hormones are stored inside the follicles of the gland, at concentrations about 30 times larger than the concentration in blood (Guyton 1991) . In an adult, hormones are stored in sufficient amounts to supply the body with its normal requirement for 2 to 3 mo. The storage period defines the biological half-life of iodine in the thyroid, which is estimated at about 80 d in adults (ICRP 1979) . This long storage time allows most of the 131 I to decay before the hormones are released to blood, thus irradiating the thyroid gland (the radiological halflife is 8.04 d). As a result, recycling of 131 I into the blood contributes little to the thyroid dose for a given intake of 131 I. Organs other than the thyroid receive a negligible dose compared to the dose to the thyroid and are generally not considered in radiological assessments. The uptake of iodine by the thyroid, the storage time in the gland, and the thyroid mass (or size) are dependent on the age of the individual. Late teenage and adult females have, on average, lower thyroid masses than males of the same age.
Types of radiation emitted
131 I is a beta emitter. Various gamma rays follow the beta decay before stable state of 131 Xe is reached. The sum of all average beta energies per nuclear transformation is 0.19 MeV. The total gamma energy emitted is 0.38 MeV/nt.
Biokinetic model for 131 I In this paper, dose coefficients for the thyroid gland are calculated using the most recent data on the mass of the thyroid obtained by ultrasonography, and the most important contributors to the uncertainty in the thyroid dose coefficients are identified. Dose coefficients for organs other than thyroid are not addressed.
The amount of radioactivity present in the thyroid is estimated using a biokinetic model containing two compartments: plasma and thyroid (Killough and Eckerman 1986) . This model neglects the recycling of iodine, which is a very good approximation for adults and teenagers, but it could underestimate the thyroid dose by no more than 10% for very young children, who have a more rapid turnover of iodine.
The dose coefficient for 131 I is given by the following equations:
and The specific effective energy (SEE) is the energy deposited per unit mass of thyroid from the nuclear transformations produced by an activity of 1 Bq stored in the thyroid gland for 1 d. SEE depends on the fraction of energy absorbed in the gland. The largest contribution to the SEE is the non-penetrating radiation (beta radiation, conversion electrons, and Auger electrons), which is essentially all absorbed in the thyroid. The contribution of the penetrating radiation (gamma and x radiation) is much less important. The SEE can be empirically expressed as a function of thyroid mass (M th ):
If the mass of the thyroid is expressed in grams, the fitted parameters are g ϭ 0.406, h ϭ 0.01014, and p ϭ Ϫ0.666 (Killough and Eckerman 1986 Derivation of the removal rates from blood ( 1 ) and thyroid ( 2 ) is based on measurements of iodine levels in the thyroid after an intravenous (I.V.) injection of a known amount of radioiodine. Normally, the maximum activity in the thyroid is observed about 24 h (t max ) after injection, after which it decreases slowly. The activity level is measured at (at least) two moments of time (t 1 and t 2 ) after the injection. The measurements are usually performed 24 -48 h (close to the peak activity) and about 15 d after the injection. Based on this, an "apparent" half-life (TЈ) describing the decline of the activity of iodine in the thyroid can be determined. The rate constants of iodine in the blood ( 1 ) and thyroid ( 2 ) are derived from the measured "apparent" half-life (TЈ), which depends on age and sex (Killough and Eckerman 1986 ).
The measured "apparent" biological half-life (TЈ) and the fraction of iodine taken up by the thyroid from the blood (a) were reviewed by Dunning and Schwartz (1981) , who found that the observed values follow lognormal distributions. They grouped the data in four age groups: (a) newborns, (b) children ages 0.5 to 2 y, (c) children and teenagers ages 6 to 16 y, and (d) adults (age Ͼ18 y).
For the uptake fraction (a), the fitted lognormal distributions reported by Dunning and Schwartz (1981) produce values larger than 100%, which do not have any physical significance. Also, other investigators (Van Middlesworth 1954; NCI 1997) indicate that the uptake fraction should slowly decrease with age at exposure, a fact not completely reflected by the data from Dunning and Schwartz (1981) . To avoid uptake fractions larger than 1, log-triangular distributions have been used in this study ( Table 2 ). The modes of these distributions were chosen to reproduce a slow decrease of the uptake fraction with age (Van Middlesworth 1954; NCI 1997) .
The apparent half-life was assumed to have a lognormal distribution with GSD of 1.8 for all age groups. The medians of the distributions agree with the general observation that iodine turnover by the thyroid is greatest for infants and decreases with age at exposure. Piecewise linear interpolation between age groups was done by assigning the reported distributions (Table 2 ) to ages 0 (newborn), 1, 15, and 20 y.
Absorption from the gastrointestinal tract
Currently, ICRP assumes that iodine absorption from the gastrointestinal tract into blood is extremely rapid and complete. In reality, the absorption is very large, but probably never 100%, because of, for instance, incomplete digestion. Thus, it is reasonable to assign a small variation to this absorption fraction. In this study a uniform distribution between 90% and 100% was selected to describe the fraction of 131 I absorbed from the gastrointestinal tract (f 1 ). Table 2 . Probability distribution functions describing the uncertainty in the biological half-life (TЈ) and the fractional uptake from blood to thyroid (a) based on the data reviews by Schwartz (1981) and NCI (1997 Dunning and Schwartz (1981) : newborn ϭ Ͻ0.5 y; child ϭ 0.5-2 y; adolescent ϭ 6 -16 y; adult ϭ Ͼ18 y. b For the lognormal distributions, "lower" and "upper" limits represent the 2.5 th percentile and the 97.5 th percentile, respectively. For the log-triangular distributions, they represent the minimum and the maximum values. c For the lognormal distributions, the "central" value represents the median of the distribution. For the log-triangular distributions, it represents the mode.
Thyroid mass
Numerous studies report measurements of the thyroid mass obtained by autopsy (Mochizuki et al. 1963; Kereiakes et al. 1965; Kay et al. 1966; Dunning and Schwartz 1981; Killough and Eckerman 1986) . However, most of the sets of measurements are incomplete, either because some age groups were not included or because few measurements are available for a specific age group. Modern ultrasonography methods are superior to autopsy because they can be used to determine the thyroid volumes in members of large populations. The masses of the thyroids can be calculated from the measured volumes using the normal density of the thyroid tissue. As a result, better distributions of the thyroid masses in the population are becoming available. Ultrasonography is also a superior method because is not subject to the errors induced the actual harvesting of the tissue. Fast removal and weighting of the thyroid is required during autopsy to avoid the loss of blood, but, due to the butterfly shape of the thyroid, removal of additional tissue is likely, especially for thyroids of small children.
Ultrasonography has shown smaller thyroid masses in children than those obtained by autopsy (Gutenkunst et al. 1986; Likhtarev et al. 1993) . Small thyroid masses will produce larger dose estimates for a given amount of ingested 131 I. A large body of ultrasound data (Table 3 ) was recently reviewed by Bier (1996) . The values reported by Bier (1996) are weighted averages across several studies obtained using the number of measurements reported in each study. He found a clear trend towards lower values of the thyroid mass obtained by modern ultrasonography as compared to similar data obtained from autopsy ( Fig. 1 ). For ages 0 -15 y, the average thyroid mass measured by ultrasound is 75% of that measured by autopsy. This fraction increases to about 90% as the age approaches 15 y, indicating that, as the thyroid mass increases, the ultrasound and autopsy measuring techniques tend to produce more nearly similar results. For adults (over 18 y), the autopsy data (Mochizuki et al. 1963 , cited by ICRP 1975 give an average thyroid mass of 17.5 g for males and 14.9 g for females. The difference between the ultrasound and autopsy measurements observed for age 15 y can be used to predict the thyroid mass in adults. This method indicates a thyroid mass of 0.9 ϫ 17.5 g ϭ 15.75 g for adult males, and 0.9 ϫ 14.9 g ϭ 13.4 g for adult females. These values (assigned to age 25 y) were used in our calculations.
The issue of interindividual variability of the thyroid mass was not addressed by Bier (1996) . To investigate interindividual variability, the data from Bier (1996) were compared to data from the countries of the former Soviet Union (FSU; Yureiva et al. 1994; Derzhitskiy et al. 1994; Averichev et al. 1994; Avramenko et al. 1994; Danilyuk et al. 1994; Fig. 2) . The data from the FSU, obtained by ultrasound measurements, report the distributions of thyroid mass in the population of school-age children from areas affected by the Chernobyl accident. In some cases, these distributions show a trend toward higher values of thyroid mass than those reported by Bier (1996) , probably because of abnormal levels of stable iodine in the diet of the children from FSU. However, for (Bier 1996) . The vertical lines represent the 95% confidence interval from statistical analysis of data. The continuous and dashed lines represent 3rd order polynomial curves fitted to the ultrasound and autopsy data, respectively.
a given age group, the distribution of thyroid masses observed in the FSU children, normalized for a central value of the thyroid mass for that age group, gives an indication of the interindividual variability for any population of children. A geometric standard deviation was obtained from the comparison of FSU data with Bier (1996) data for which lognormal distributions with different GSDs were applied. A GSD of 1.5 was determined to be the best representation of uncertainty in thyroid mass due to interindividual variability of the thyroid mass. In conclusion, the uncertainty in the thyroid mass is expressed using lognormal distributions having average values from Bier (1996 ; Table 3 ) and a geometric standard deviation of 1.5 applied to all age groups.
Results and discussion-131 I The estimates of the 95% confidence intervals for the age-specific thyroid dose coefficients are shown in Fig. 3 for females and are listed in Table 4 for selected ages at exposure and both sexes. A common geometric standard deviation (GSD) of 1.7 can be used to describe the uncertainty in the dose coefficients for ingestion of 131 I for all age groups and both sexes. For ingestion of 131 I by infants a GSD of 1.8 is appropriate. The medians of the uncertainty distributions for each dose factor are close to the values recommended by ICRP (2000) . However, the ICRP dose coefficients are regarded as averages across large populations, and thus they should also be compared with the means of the uncertainty distributions. The estimated means are 10 -40% larger than the ICRP coefficients. One expects larger values for dose coefficients estimated in this work because lower values for thyroid masses and larger values of uptake fractions (a) for children were used. However, the "apparent" biological half-life (TЈ) used in this study produces a removal rate of 131 I from the thyroid gland greater than the removal rate of 131 I from the thyroid used by ICRP, a difference that reduces the increase introduced by the lower thyroid mass and the faster clearance of iodine from plasma.
The sensitivity analysis identifies the variables that are major contributors to the uncertainty in the estimates (2000) . The dotted lines represent the lower and upper bounds of a 95% confidence interval. For childhood exposures (age Յ15 y), the thyroid dose coefficients for males are the same with those for females. For adults, the dose coefficients for males are about 15% lower than dose for females. Bier (1996) and from the Gomel and Bryansk Regions (former Soviet Union), which were affected by the Chernobyl accident. The uncertainty in the thyroid masses reported by Bier (1996) was described by a lognormal distribution with a geometric standard deviation of 1.5. The upper and lower bounds delimit a 95% confidence interval. The numbers in parentheses represent the number of samples for the FSU data.
Fig. 2. Comparison of thyroid masses from
of the dose coefficients. The analysis was performed for selected age groups. The major contributor to the uncertainty in the dose per unit intake is the thyroid mass (about 50%), followed by the fractional uptake from blood (a; 35-40%). The biological elimination rates from blood ( 1 ) and from the thyroid ( 2 ) have a low contribution that also decreases as the age at exposure increases. The contribution of uncertainty in the absorption from the gastrointestinal tract to blood is negligible at all ages.
Therefore, to estimate the thyroid dose for a given individual, one should ideally obtain specific values for the thyroid mass and the fractional uptake for that individual, and concentrate less on the retention time of the iodine in the thyroid gland. The thyroid mass for a given individual could be obtained by direct measurement of thyroid volume using ultrasound techniques or by using relationships between thyroid mass and other easy-to-measure characteristics such as body mass or body height. Further research is necessary to identify a method for assessing the fractional uptake of iodine by the thyroid gland as a function of individual characteristics (without additional use of radioiodine as a tracer).
The dominant contribution of the thyroid mass to the uncertainty in the dose coefficients also has another implication. For an individual who has multiple exposures at different ages, the dose coefficients are highly correlated, and this correlation must be taken into account in the calculation of doses. That is, if an individual has a relatively small thyroid in one year, it is likely that he will still have a relatively small thyroid in the following years, and thus a relatively high dose coefficient applies to him in every year. However, the correlation is not complete because some variation in the relative size of the thyroid may occur, but, more importantly, because, the fractional uptake (a) may vary by some degree from one exposure to the next, according to the metabolic state of the individual. When calculating thyroid doses from multiple intakes of 131 I, it is better to consider full correlation between dose coefficients for each exposure than to assume that they are independent, so the uncertainty in total dose is not underestimated.
Cs
Cesium biokinetic is correlated with potassium distribution and movement in the human body due to the good chemical equivalence (Leggett 1986 ). After ingestion, cesium (as potassium) is distributed rather uniformly throughout the body, and thus the doses to all organs are similar. This study concentrates on the dose coefficients for ingestion of 137 Cs by healthy adults. Sex differences are taken into account for the biokinetic parameters, for the gamma energy absorption fractions, and for individual organ masses.
Emitted energies
137 Cs is a beta emitter that decays 94.6% of the time into 137m Ba, which further decays into its stable state by emitting 661 keV gamma radiations (89.8% of the time). Per nuclear transformation of 137 Cs, the energy of emitted gamma and x rays is 0.564 MeV, while the average energy of emitted beta radiation is 0.249 MeV (ICRP 1983) . The uncertainty in these energy values is thought to be small compared to other sources of uncertainty that affect the dose coefficients, so it was neglected.
Absorption from the gastrointestinal tract
Most studies agree that cesium in inorganic form is totally and rapidly absorbed into blood from the gastrointestinal tract (ICRP 1975 (ICRP , 1989 Leggett 1986 ). However, in some instances (e.g., 137 Cs in contaminated meat ingested by humans), the absorption fraction (f 1 ) was found to be marginally lower, varying from 72% to 85% with a mean of 80.4% (Talbot et al. 1993) . In this paper, values in a range from 80% to 100% were considered to be plausible for f 1 , and a triangular distribution having a minimum of 80% and a mode and a maximum of 100% was chosen to represent the uncertainty in this parameter. The average of this distribution is 93%.
Biokinetics of
137 Cs Absorbed cesium is easily transported to all organs and tissues. The most widely accepted approach is that cesium is uniformly distributed in the body. This approach is considered valid for the calculations done in this work. Cesium is excreted in urine and feces, with the amount in urine being about 4 times larger than that in feces.
Since the half-life of the 137 Cs in-growing decay product is very short (2.55 min), a reasonable assumption is that the sites of decay for 137m Ba should be the same as those of its parent 137 Cs. The location of 137m Ba when it decays is important because a large portion of the energy responsible for the delivered dose comes from 137m Ba and not from 137 Cs. There is some experimental evidence that 137m Ba migrates from its parent. By determining the distribution of 137 Cs and 137m Ba in rats within a few minutes after death, Wasserman et al. (1959) demonstrated some dissociation of 137m Ba from administered 137 Cs. According to this evidence, 137m Ba would follow the biokinetics of elemental barium, which has some affinity for bone and is also rapidly transferred from blood to the intestinal contents. The doses to the bone and to the gastrointestinal tract organs might change as a result of such a change in the biokinetic model. However, this evidence is inconclusive, and it has not yet been incorporated into the ICRP models. Such a modification of the models was not considered in this work, either.
The currently accepted biokinetic model consists of two compartments for the total body (ICRP 1979 (ICRP , 1989 (ICRP , 1993 , one with a fast and one with a slow turnover of cesium. The fraction transferred to the fast turnover compartment is denoted as a, and the default value recommended by ICRP is 10%. The default ICRP values for the biological half-times for the fast and the slow compartments in adults are T 1 ϭ 2 d and T 1 ϭ 110 d, respectively. The longest biological half-life is much smaller than the radioactive half-life of 137 Cs (30 y). Parameters a, T 1 and T 2 are related to the amount of potassium in the body. Using experimental data, Leggett (1986) derived relationships between these parameters and the amount of potassium in the total body.
Denoting by K t the amount of potassium in the whole body (expressed in grams), the relationships for males are
In the above equations, the half-lives are expressed in days, and parameter a is a unitless fraction. Similar relationships were derived for females (eqn 5a, b, c) for an amount of potassium greater than 43 g (Leggett 1986 ). For amounts of potassium less than 43 g, the relationships for males (eqn 4a, b, c) apply for females as well:
In this study, the amount of potassium in the total body (K t ) was estimated by multiplying the concentration of potassium in the human body [g kg Ϫ1 of total body; Anderson (1963) ] and the human body mass (kg) as provided by ICRP Publication 23 (1975; Table 5 ). The uncertainty distribution for K t is calculated by propagating the uncertainties in the reported concentration of potassium (K t ) and whole body mass. Then, parameters a, T 1 , and T 2 are derived using eqns (4) and (5) ( Table 6 ). Similar distributions for parameters a, T 1 , and T 2 are reported by Schwartz and Dunning (1982) , but they found little or no correlation between these parameters and body mass or potassium amount.
Absorption fraction (AF)
The energy of the emitted beta radiation is assumed to be completely absorbed within each organ. The absorbed fractions [AF(T4S)] for gamma radiation are obtained by multiplying the specific absorbed fraction [SAF(T4S)] reported by ICRP (Stabin et al. 1995; Cristy and Eckerman 1987) by the default mass of each target organ (T). For 137 Cs, the source of radiation (S) is the whole body. The absorbed fractions for gamma radiation are affected by uncertainties due to the lack of knowledge about the precise position and shape of each target organ, the relative size of the whole body and of each target organ, and by statistical uncertainties introduced by the methods used to solve the radiation transport problem.
No full quantification of these uncertainties is available.
However, given the current advancements in the Monte Carlo methods for radiation transport, it is expected that the statistical uncertainties are much smaller than the uncertainties related to the size and position of different organs.
The absorbed fraction for similar target organs in males (body weight ϭ 70 kg) and in females (body weight ϭ 58 kg) varies by less than 30% for all organs other than bone and muscle. For most organs the variation in the absorbed fraction is even less than 20%. The variation in the absorbed fraction for muscles is about 40% because males have less fat and more muscle than females. The 95% confidence interval for the variation of the body mass in adult males is 48 to 90 kg (ICRP 1975) . For females, the 95% confidence interval is 40 to 74 kg (ICRP 1975) . As the body mass varies within these confidence intervals, the absorbed fraction varies by more than 30%, but the variation is probably not larger than 50%. In the absence of better information, the uncertainty in the absorbed fraction for gamma radiation for all target organs was assumed to be 50%. A loguniform distribution with the limits defined by a factor of 1.5 above and below the ICRP recommended absorbed fraction was used in this paper. a The sources of information are given in the text. The uncertainties are described by probability distributions, which in turn are described by the shape and by the parameters 1 and 2. The central value of the distribution is given for comparison purposes. For instance, the mass of adrenals in males is described by a lognormal distribution with a mean ϭ 14 g and a standard deviation of 3 g. The mass of liver for males is described by a lognormal distribution with a geometric mean (GM) ϭ 1.8 kg and a geometric standard deviation (GSD) ϭ 1.21. For kidney, the distribution is triangular with a minimum of 0.232 kg and a maximum of 0.375 kg. The mode is 0.31 for males and 0.275 kg for females. b SI ϭ small intestine; ULI ϭ upper large intestine; LLI ϭ lower large intestine; RBM ϭ red bone marrow. c Mass of the total body minus the mass of the gastro-intestinal tract and bladder contents (1.1 kg). First row of numbers is for the reference population (ICRP 1975) . The second row is the mass for the U.S. population age 20 y and older from CDC's most recent National Health and Nutrition Examination Survey (NHANES; CDC 2003). 
Organ masses
Probability distributions describing the uncertainty in the organ masses were developed for each target organ (Table 7 ) from detailed information presented by ICRP (1975) . The uncertainties describe, to the extent possible, the inter-individual variability of the mass for that particular organ. In some cases, the original publications cited by ICRP Publication 23 were used for more detail and additional explanations [e.g., Spitzka (1904) for the weight of the lungs; Tipton and Cook (1969) and Eve (1966) for the gastrointestinal tract organs]. For thyroid gland, the mass estimated using ultrasound measurements of the thyroid volume was used as described earlier in this paper. Data on the bone surfaces and the red bone marrow are summarized by ICRP (1995) , and a discussion of the uncertainties is given by Apostoaei (2001) .
The whole-body mass for adults was taken to be 70 kg for males (SD ϭ 10.5 kg) and 58 kg for females (SD ϭ 8.6 kg; ICRP 1975). These distributions describe a population of 20 -30-y-old individuals, which was considered the "reference" population in this study. The contemporary U.S. adult population (ages 20 y and older) has a distribution of the whole-body mass values biased towards larger values. According to the data for recent years (1988 -1994) reported by CDC's National Health and Nutrition Examination Survey (NHANES; CDC 2003), the whole body mass of the U.S. males is 81.5 kg (SD ϭ 16 kg) for ages 20 y and older. Similarly, the whole body mass of U.S. females is 68 kg (SD ϭ 18.9 kg) for age 20 y and older. The dose coefficients presented in this paper are estimated using the reference population defined using the ICRP values. However, dose coefficients obtained using the U.S. population whole body mass distributions are also provided.
The individual organ masses were assumed to be fully correlated with the whole body mass. That is, it was assumed that an individual with a large body mass will also have a large mass for the muscles, lungs, liver, gastrointestinal tract, or other organs. This correlation should not be regarded as a strict relationship. Obviously, the mass of a given organ may depend on other physical parameters (e.g., body height) or on metabolic status (e.g., hormonal balance). However, it is more realistic to use such a correlation than to assume that individual organ masses are entirely independent of the total body mass.
RESULTS AND DISCUSSION-137 Cs
The probability distributions obtained for the estimated dose coefficients for ingestion of 137 Cs can be fitted very well by either normal or lognormal distributions. The mean and the median of each dose coefficient are almost equal. The geometric standard deviations (GSD) are about 1.24 for males and 1.40 for females (Table 8) , and the coefficients of variation (CV) are about 25% for males and 40% for females. The larger uncertainty observed for females is due to the larger variation of the amount of potassium in a population of females (Table 5) . Even though the body weight has a similar variation in the population for males and for females, the concentration of potassium has a larger variation for females; that is, for the same body weight, the concentration of potassium varies more among women than among men. However, the magnitude of the uncertainty is very similar among organs because the main contributor to the uncertainty in the dose coefficients (more than 80%) is the biokinetic model, which affects all organs in the same way. The mass and the absorbed fraction for each individual organ have only a small impact on the overall uncertainty. Also, the effect of uncertainty assigned to the fraction absorbed from the gastrointestinal tract (f 1 ) is negligible.
The estimated 95% confidence intervals for the dose coefficients encompass the ICRP values for 137 Cs (Fig.  4) . However, the averages (and medians) of the estimated dose coefficients are lower than the dose coefficients currently reported by the ICRP for adults. The differences range from 2-18% for males and 2-27% for females, depending on the organ. The reason for the lower dose coefficients is the shorter retention of 137 Cs predicted by Leggett (1986) (i.e., T 2 ϭ 101 d for males and T 2 ϭ 85 d for females; Table 6 ), as compared to the retention assumed by ICRP (T 2 ϭ 110 d). A secondary reason is the fraction absorbed from the gastrointestinal tract (f 1 ): ICRP recommends a default f 1 ϭ 1, while values slightly less than 1 were used in this study. The differences are uniform among organs, again due to the same biokinetics.
The results shown here (Table 8) are for ingestion of 137 Cs by adults. If similar calculations were to be performed for children, no sex differences in the dose coefficients are expected for exposures at ages less than 7 y. For children above 7 y of age, slight changes with sex should be observed in the 137 Cs biokinetic parameters (Leggett 1986 ). Above 10 y of age, males and females start showing differences in the concentration of potassium (Anderson and Langham 1959) , and for individuals older than 15 y, the total body mass and the masses of many organs are sex-dependent. Uncertainties in the 137 Cs ingestion dose coefficients for exposure in childhood are expected to be larger than the uncertainties in the dose coefficients for adults (GSD Ͼ1.4 for males and GSD Ͼ1.6 for females).
For a larger body weight, the calculations show a longer residence time of 137 Cs in the body, which would normally lead to a higher dose due to a larger amount of energy deposited in the body. However, since the dose is the energy divided by the mass, the effect of the longer residence time is practically eliminated by the higher body mass. Thus, the dose coefficients for 137 Cs (Table 8) are not affected significantly when the body mass for the U.S. population (Table 7) is used. The dose coefficients in Table 8 can be applied to assessments for members of the U.S. population.
Sr
This study focused on the uncertainties in the dose coefficients for ingestion of 90 Sr, and it has explored the changes with age and the effect of sex in the dose coefficients for healthy adults. The available data on 90 Sr biokinetics in humans, on the energy deposited in each organ, and on the masses of the organs were collected and analyzed to derive probability distribution functions describing the uncertainty in each parameter of the model. Necessary correlations between parameters were imposed before the uncertainties were propagated through the biokinetic and dosimetric models using Monte Carlo methods. Throughout this work, the uncertainties represent, to the extent possible, interindividual variation of the given parameter. In those cases when data were insufficient to clearly describe the interindividual variability, the uncertainty describes the range of possible values obtained by professional judgment from the available information.
The ICRP's most recently developed biokinetic model developed for ingestion of 90 Sr was employed for the estimation of the dose coefficients ( Fig. 5; ICRP   Fig. 4 . Comparison of two dose coefficients for ingestion of 137 Cs estimated in this study to the most recent values recommended by ICRP (2000) . For the values estimated in this study, the central value is the median, and the vertical lines represent the 95% confidence interval. The distributions obtained for males are well represented by lognormal distributions, while the distributions for females deviate slightly from lognormal (i.e., they are closer to normal distributions). 1993 ). The movement of strontium in the human body is assumed to be well described by a set of first-order differential equations of the form
where n is the number of compartments, j,i are the transfer rates between compartments (from j to i), i is the removal rate from compartment i, R is the radioactive decay rate, and i is the compartment representing the current "source" organ S. In Fig. 5 the transfer rates are expressed as j,i ϭ a j,i ϫ j , where a j,i is the fraction of material leaving compartment j that reaches compartment i, and j is the removal rate from compartment j. The sum of all fractions leaving a compartment must be equal to 1 (i.e., i ϭ 1 ͚ a j, i ϭ 1). The biokinetic model for 90 Sr is described by eighteen compartments (Q i , i ϭ 1,18) and has fifteen nonzero removal rates ( i , i ϭ 1,15), sixteen fractional transfers between compartments (a j,i , i,j ϭ 1,16) (counting only the ones different from 0 and 1), and a total of 28 transfer rates ( j,i ) between compartments. The parameter values, their dependencies, and their interrelationships have been described previously by Apostoaei (2001) . The concentration of 90 Sr predicted by the biokinetic model was used to determine the number of nuclear transformations in each organ. Then, organ specific dose coefficients were computed based on the principles of internal dosimetry (ICRP 1979; Eckerman 1994) by using the mass of the target organ (M T ) and the fraction of energy emitted from each source organ (S) that is absorbed in the organ of interest [AF(T4S)].
The organ-specific dose factors were calculated for three major cases defined as follows:
• Case A1: The biokinetic parameters are for an adult and show no age dependency. 90 Y, the radioactive The first step in the determination of uncertainties in ingestion dose coefficients is to quantify the uncertainty in the parameters of the biokinetic and dosimetric models. The parameters are based on data obtained as a result of investigations of strontium metabolism in humans subject to scientific experiments and accidental exposures. Human data on chemically similar elements (e.g., calcium) were used to complement the human data for strontium. The analysis of data for deriving model parameter distributions follows the logic used by Leggett (1992) to select the default parameter values for the ICRP biokinetic model for 90 Sr. No statistical fitting or parameter optimization was performed by Leggett (1992) for the entire strontium model, but "initial selections were made for individual parameter values based on the best available evidence for the pathway considered, and then, due to the interdependence of the parameter values, repeated 'tuning' of initial selections was performed until satisfactory fits to available human data were obtained." A similar method was applied in this work. However, the parameters were derived as probability distribution functions, and comparisons with the experimental data consist of two equally important aspects: a) the predicted central value should reproduce the observed central tendency of the data, and b) the range of the predicted values at any moment in time should cover interindividual variation of the data for that moment. For example, Fig. 6 shows predicted activity concentrations of strontium as a function of time against observed concentrations obtained in humans given I.V. injections of radioactive strontium.
RESULTS AND DISCUSSION-90 Sr
The doses per unit of ingested activity of 90 Sr were calculated for 22 organs. However, because of the specific biokinetics of 90 Sr, only 7 organs show different doses (i.e., bone surface, red bone marrow, bladder, stomach, small intestine, upper large intestine, and lower large intestine), while the rest of the organs receive the same dose. The dose coefficients were calculated for each sex separately, but also for both combined. The latter calculations follow the ICRP approach. That is, the biokinetic parameters represent both sexes combined, and the organs are defined as for the ICRP hermaphrodite phantom (organ masses represent a male, but the phantom contains female organs such as breast and uterus). The sex-dependent dose coefficients are presented for Case A1 for an exposure at age 20 y (Table 9 ). These dose coefficients are obtained by integrating up to age 70 y, and thus represents committed doses. The sexindependent dose coefficients obtained for cases A1, A2, and B1 described above are compared with the ICRP coefficients in Fig. 7 . Median values estimated in this work are slightly lower than the values published by ICRP (1993) . One of the main reasons for this difference is the lower value for uptake from the gastrointestinal tract (f 1 ) used in this work. ICRP (1993) used f 1 ϭ 0.3, while, in this work, the central value of the distribution for f 1 is 0.23 (Apostoaei 2002) , which is 23% lower than the ICRP value. Also, the elimination rate of strontium from trabecular bone derived in this work (0.22 y Ϫ1 ; Apostoaei 2001) is larger than the value used by ICRP (0.18 y Ϫ1 ), a difference that affects mainly the dose coefficients for the bone surfaces and to red bone marrow. In addition, for the organs of the gastrointestinal tract, ICRP (1993) assumes no reduction of the dose to the sensitive cells in the walls of an organ due to the potential attenuation of the beta radiation emitted from the organ contents. In this work, a reduction factor accounting for this effect was used as described by Apostoaei (2001) . This reduction factor is important especially for the upper and lower large intestine, for which the dose from radioactivity in the organ contents dominates over the dose from the systemic radioactivity.
Age dependency
Only four of the biokinetic parameters were identified to have a variation with age for adults. These four parameters are the fractional transfers of strontium from plasma to cortical and trabecular bone, and the removal rates from the cortical and trabecular bone, respectively. For most of the other parameters there are not enough data to fully analyze the age dependency. However, the variation with age for most biokinetic parameters (if any) is expected to be very mild. For the absorption from the gastrointestinal tract (f 1 ), the transfer of strontium to excreta, and the half-life of strontium in the nonexchangeable bone volume there are sufficient data for a rigorous statistical analysis, but no statistically significant age dependency is evident. In addition, no age dependency is observed for the fraction of the energy absorbed in an organ, and the age dependency in the organ masses has a negligible affect on the dose coefficients compared to the size of the uncertainty ranges for the same dose coefficients.
The variation of the dose coefficients with age at exposure is shown in Fig. 8 , where the dose coefficients represent dose delivered over a period of time from exposure to age 70 y. The variation of the dose coefficients with age at exposure is important for estimation of doses from continuous exposures. Such doses can be obtained by multiplying the intake by the dose coefficients at each age and then summing over all ages.
Dose coefficients as a function of attained age (i.e., the dose from the time of exposure to a specified age) can also be useful, for example, for calculating quantities such as the probability of cancer causation from a particular exposure. The variation of the dose coefficients with attained age is shown in Fig. 8 for exposures at age 20 y.
The differences between the dose coefficients obtained in Case A1 (age-independent parameters) and in Case A2 (age-dependent parameters) are small compared with the magnitude of the uncertainties in the dose factors and compared to the variation of the dose coefficients with age at exposure and attained age. Also, the uncertainties for the two sets of dose coefficients are comparable. These results are not surprising because dose is a cumulative quantity. Even though some parameters are age dependent, when the dose is integrated over time, the result is similar to that obtained with ageaveraged parameters values.
In the age-at-exposure curve for Case A2, a minimum is observed for exposure at age 35 y (Fig. 8) ; this is the result of the low plasma to bone transfer for that age (Apostoaei 2001) . The largest difference between Case A1 and Case A2 is about 40% (observed for bone surfaces and red bone marrow; Fig. 8 ). This difference is small compared to the uncertainties in the dose coefficients (a factor of 6 for bone surfaces and 5 for red bone marrow).
The attained-age curves also show that the committed dose is essentially reached about 30 y after exposure for the bone surfaces and 20 y after exposure for the red bone marrow and for organs other than bladder and lower and upper large intestine (Fig. 8) . The dose to the latter organs is dominated by the dose from the activity in the contents of these organs, and thus the committed dose is reached much faster (in about 10 y for bladder and in 1 or 2 y for the upper and lower large intestine; Apostoaei 2001). (ICRP 1975) for whom the whole-body mass is 70 kg for males and 58 kg for females (see Table 7 for assigned uncertainties).
The uncertainty in the dose coefficients does not change significantly with age at exposure or attained age for bladder, the gastrointestinal organs, or the soft tissue organs. For bone surface the uncertainty varies with age at exposure from a GSD of 2.5 at age 20 y to a GSD of 2.0 at age 69 y, while for red bone marrow it varies between the same ages from a GSD of 2.3 to a GSD of 1.8. The variation with attained age of the uncertainty for these two organs is comparable in magnitude to the variation with age at exposure with the difference that the largest uncertainties occur at the highest attained ages.
Sex dependency
Of all biokinetic parameters analyzed for 90 Sr, only the removal rate of strontium from the trabecular bone was found to depend on sex, and that only slightly. For   Fig. 8 . Age-at-exposure (left column) and attained-age (right column) dependency of the dose coefficients from ingestion of 90 Sr. In the left column, the values represent the dose per unit intake delivered from the indicated age at exposure to age 70 y. In the right column, the values represent the dose per unit intake at age 20 y to the indicated attained age. The vertical lines are the 95% confidence intervals about the estimated dose factors. "Other organs" refers to organs other than the bone structures, bladder, and gastrointestinal tract. females, the removal rate is 0.26 y Ϫ1 , while values from 0.15 y Ϫ1 to 0.21 y Ϫ1 are obtained for males (average of 0.18 y Ϫ1 ). For adults, the removal rates from the cortical bone are about six times less than the removal rates from the trabecular bone (ICRP 1995) . Thus, the removal rates for cortical bone can be estimated as 0.26/6 ϭ 0.043 y Ϫ1 for females and 0.18/6 ϭ 0.030 y Ϫ1 for males. These values are well confirmed by the recent analysis of the whole-body 90 Sr measurements in residents living along Techa River downstream of Mayak, the Russian nuclear weapons facility (Shagina et al. 2002 (Shagina et al. , 2003 . This analysis indicates removal rates from cortical bone of 0.043 y Ϫ1 (GSD ϭ 1.42) for females and 0.029 y Ϫ1 (GSD ϭ 1.75) for males. When reference calculations of the dose coefficients were performed using biokinetic parameters for both sexes combined, removal rates equal to 0.22 y Ϫ1 and 0.038 y Ϫ1 were used for trabecular and cortical bone, respectively.
For the rest of the parameters the data are inadequate to analyze sex differences (e.g., data are available for males only), or no significant difference between sexes is observed (e.g., the uptake from the gastrointestinal tract or the fraction of excreted strontium).
Differences between males and females may reasonably be expected in the fraction of energy absorbed in the bone structures. The fraction of energy absorbed in the bone tissue depends on the bone mineral density, which is larger in males than in females. However, it is unknown at this time if the difference in the bone density has a significant impact on the absorbed fraction.
The masses of soft tissue organs depend on sex, and the differences in masses between sexes are well documented for many organs (Table 7) . However, the dose coefficients for these organs from 90 Sr do not depend on the mass of the organ. Rather, the dose coefficients calculated for the "rest of the body" (i.e., the whole body less the skeleton and contents of the gastrointestinal tract and bladder) are assigned to each of the soft tissue organs. These dose coefficients depend on the mass of the whole body, which in turn is lower for females than for males. In the reference population used in this study the mass for females is 58 kg and for males is 70 kg. For the U.S. population the mass is 68 kg for females and 81.5 kg for males.
Sex-specific dose coefficients for ingestion of 90 Sr were estimated by using the sex-dependent factors discussed above for both the reference population (Table 9 ) and the U.S. population (Table 10 ). An inspection of Tables 9 and 10 reveals that the difference between the soft-tissue dose coefficients for the U.S. population and for the reference population is small (Ͻ15%) compared to the size of the uncertainties in the same dose coefficients (a factor of 3 from the median to the upper bound). a ST ϭ stomach; SI ϭ small intestine; ULI ϭ upper large intestine; LLI ϭ lower large intestine. b The dose coefficients reported in Table 9 are for a reference population for which the whole-body mass is 70 kg for males and 58 kg for females (ICRP 1975) . This table presents the dose coefficients for the U.S. adult population (Table 7) , which has a larger whole body mass, leading to smaller doses to the soft tissues, including the walled organs such as the gastrointestinal tract organs and bladder.
The uncertainties in the soft tissue dose coefficients are similar for males and females. The dose coefficients for the walls of the gastrointestinal tract contain a contribution of the radiation emitted from the content of these organs. This contribution is small for stomach, and is dominant for the lower portion of the large intestine. Thus, the dose coefficients for stomach are larger by 20% for females than for males (i.e., like any other soft tissue), but practically no difference between sexes is obtained for the lower large intestine.
The dose coefficients for bone surface and red bone marrow are lower for females than for males because females show, on average, a larger loss of strontium from bone structures. However, females have a lower red bone marrow mass than males (due to a lower skeleton mass and volume), while no difference between males and females is considered for bone surfaces (Table 7) . Thus, for bone surfaces the dose coefficients for females are lower than the dose coefficients for males by about 25%. For the red bone marrow, the difference between sexes is only 5%. The uncertainties in the bone surface and red bone marrow dose coefficients for females are larger than the uncertainties in the same dose coefficients for males ( Table 9 ). The removal rate of strontium from bone is not only larger for females, but it has also a larger variation in the population than the removal rate for males. The magnitude of the uncertainties in the individual dose factors is much larger than the differences between the dose coefficients for the two sexes (Fig. 9) (ICRP 1979) indicate that yttrium tends to accumulate in liver more than in other soft tissue organs and that a substantially larger fraction of yttrium is transferred from plasma to bones than in the case of strontium.
To investigate the potential impact of the different kinetics, dose coefficients were estimated using the kinetic model of yttrium proposed by the ICRP (ICRP 1979; Eckerman et al. 1999) . This model specifies that yttrium leaves plasma with a half-time of 0.25 d, and that 50% goes to bone, 25% to excretion, 15% to liver, and 10% to other soft tissues. In all organs of the body 90 Y is retained indefinitely. The uptake from the gastrointestinal tract (f 1 ) is 10 Ϫ4 . The transfer from plasma to trabecular and cortical bone is assumed to be the same as for 90 Sr (i.e., trabecular bones receive 50% more yttrium than the cortical bones). Similarly, the fraction that goes to excretion is divided 1/4 to feces and 3/4 to urine, the same as for 90 Sr. The organ dose coefficients obtained using this kinetic model for 90 Y are practically identical to the doses obtained when 90 Y is assumed to have the same kinetics as its parent, 90 Sr. The only significant difference is observed for bladder, where the dose for Case B1 is lower by 50% than the dose for Case A1 (Fig. 7) . The difference is given by the half-time of yttrium in plasma, which is longer than for strontium, resulting in a lower estimate of the overall transfer from plasma to the bladder. Even though liver is considered a separate organ in the yttrium biokinetic model, the dose coefficient for liver for Case B1 is practically identical to the dose coefficient for Case A1 (less than 1% difference). That is, the results for liver are similar to the ones presented in Fig. 7 for other organs.
These calculations are based on the assumption that only 90 Sr is initially ingested. In reality, any food items or potable liquids in which 90 Sr is present can contain 90 Y in equilibrium with its parent. Thus, ingestion of 1 Bq of 90 Sr usually means ingestion of 1 Bq of 90 Y as well. Since yttrium is poorly taken up from the gastrointestinal tract (f 1 ϭ 10 Ϫ4 ) as compared to strontium (f 1 ϭ 0.23), the doses to organs other than the gastrointestinal tract are not changed because of the additional ingestion of 90 Y. The following dose coefficients to the gastrointestinal tract organs are obtained for the case when both radionuclides are ingested: a) stomach ϭ 1.7 ϫ 10 Ϫ9 Sv Bq Ϫ1 (95% C.I., 8.6 ϫ 10 Ϫ10 -3.2 ϫ 10 Ϫ9 ); b) small intestine ϭ 2.4 ϫ 10 Ϫ9 Sv Bq Ϫ1 (95% C.I., 1.2 ϫ 10 Ϫ9 -6.3 ϫ 10 Ϫ9 ); c) upper large intestine ϭ 1.3 ϫ 10 Ϫ8 Sv Bq Ϫ1 (95% C.I., 7.1 ϫ 10 Ϫ9 -2.2 ϫ 10 Ϫ8 ); and d) lower large intestine ϭ 4.3 ϫ 10 Ϫ8 Sv Bq Ϫ1 (95% C.I., 2.0 ϫ 10 Ϫ8 -1.1 ϫ 10 Ϫ7 ). uncertainties in the dose coefficients for ingestion of 137 Cs are small compared with uncertainties in the dose coefficients for ingestion of the other two radionuclides.
For ingestion of 131 I, sex differences occur only for individuals older than 15 y of age, with females having a larger dose coefficient than males due to a lower thyroid mass (Table 4 ). The 131 I dose coefficients have the same uncertainty for both males and females. For ingestion of 90 Sr, for soft tissue organs, the dose coefficients for females are larger by about 20% than the dose coefficients for males due to the average lower body mass of females. The uncertainties in these 90 Sr dose coefficients are similar for both males and females ( Table 9 ). The dose coefficients for bone surface and red bone marrow are lower for females than for males because females show, on average, a larger removal rate of strontium from bone structures. For bone surfaces the dose coefficients for females are lower than the dose coefficients for males by about 25%. For red bone marrow, the difference between sexes is only 5%. The uncertainties in the bone surface and red bone marrow dose coefficients for females are larger than the uncertainties in the same dose coefficients for males ( Table 9) .
The sensitivity analyses indicate that the uncertainty introduced by the variability in the biokinetic parameters is the dominant source of uncertainty in the ingestion dose coefficients for 137 Cs and 90 Sr. For 131 I, the biokinetic parameters contribute about 30 -40% of the total uncertainty in the dose coefficients (depending on the age at exposure), while the contribution of the thyroid mass is about 50%. The uncertainty in the absorbed fraction (the fraction of energy deposited in the target organ) is the smallest contributor to the uncertainty in the dose coefficients for most organs. The absorbed fraction is an important contributor to the uncertainty only for the upper and lower large intestine in the case of ingestion of 90 Sr. For these organs, the dose to the intestinal wall is dominated by the radiation emitted from the contents, and the estimated energy deposited in the wall is highly uncertain. The biokinetic parameters with the largest contribution to the uncertainty are a) the fractional uptake from blood to thyroid in the case of ingestion of 131 I, b) the absorbed fraction from the gastrointestinal tract (f 1 ) in the case of 90 Sr, and c) the amount of potassium in the body for 137 Cs. To reduce the uncertainty in the dose estimated for an individual, one ideally would determine the above-mentioned parameters for the specified individual. In the case of exposure to 131 I, the knowledge of the actual thyroid mass for that individual would also highly reduce the uncertainty in the thyroid dose.
